Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Long noncoding RNA X-inactive specific transcript (XIST) is an acknowledged cancer-related gene and participates in the development of SCI.
|
31778769 |
2020 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Long non-coding RNA XIST predicting advanced clinical parameters in cancer: A Meta-Analysis and case series study in a single institution.
|
31404342 |
2019 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our meta-analysis showed that XIST may be a useful common biomarker for predicting prognosis in patients with cancer.
|
30341910 |
2019 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, subgroup analysis based on cancer type revealed that lncRNA XIST expression correlated with distant metastasis in digestive cancer (OR = 2.90, 95% CI = 1.80-4.68; P < .001).
|
30653128 |
2019 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The results suggested that high expression of XIST has a significant relationship with a relatively poor overall survival for patients with malignant tumors (HR 1.82; 95% CI 1.32, 2.52; <i>P</i> = 0.0003).
|
31566056 |
2019 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The long non-coding RNA X inactive-specific transcript (XIST) has been implicated in certain human cancers, including osteosarcoma (OS), but the molecular mechanism of XIST underlying OS progression remains to be fully uncovered.
|
30651857 |
2019 |
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This review presents the current level of knowledge on the most studied cancer-related lncRNAs, such as the metastasis associated lung adenocarcinoma transcript 1 (MALAT1), the Hox transcript antisense intergenic RNA (HOTAIR), or the X-inactive specific transcript (XIST), as well as more recently discovered forms, and their potential roles in different types of cancer.
|
30654440 |
2019 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Lentivirus-mediated XIST upregulation had significant anticancer effects in CAOV3 and OVCAR3 cells by suppressing cancer cell proliferation, invasion, increasing cisplatin chemosensitivity and inhibiting in vivo tumor growth.
|
30207107 |
2018 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
XIST knockdown inhibited cancer cell proliferation and invasion in vitro, inhibited the EMT of OS cells in vitro, and suppressed subcutaneous tumor growth in vivo.
|
29384226 |
2018 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As a tumor promoter, lncRNA XIST has been reported in various malignant tumors.
|
29909347 |
2018 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
XIST was correlated with poor prognosis, which suggested that XIST might serve as a novel predictive biomarker for cancer patients, especially for patients of digestive system tumors.
|
29752340 |
2018 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
JPX increases expression levels of XIST in HCC cells, which suppresses HCC development by sponging the cancer promoting miR-155-5p.
|
30091314 |
2018 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results indicate that XIST plays a critical role in brain metastasis in breast cancer by affecting both tumor cells and the tumor microenvironment and that the XIST-mediated pathway may serve as an effective target for treating brain metastasis.<b>Significance:</b> These findings describe mechanisms of how loss of the lncRNA XIST promotes brain metastasis in breast cancer and identify fludarabine as a potential therapeutic agent that specifically eliminates XIST<sup>low</sup> tumor cells in the brain.<i>Cancer Res; 78(15); 4316-30.©2018 AACR</i>.
|
30026327 |
2018 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It was demonstrated high level of lncRNA XIST was positively correlated with larger tumor size (OR=1.89, 95% CI 1.34-2.06, P<0.001), positive distant metastasis (OR=1.75, 95% CI 1.03-2.96, P=0.038) and high-grade cancer (OR=1.64, 95% CI 1.22-2.21, P<0.001).
|
29307668 |
2018 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, the pooled results in our current work suggest that XIST is an important prognostic biomarker in cancer patients.
|
29568404 |
2018 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
XIST, one of the first found cancer-associated lncRNAs, has been frequently reported to play major role in several biological processes.
|
28771809 |
2018 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
XIST is dysregulated and acts as an oncogene or a tumor suppressor in different human malignancies.
|
30171939 |
2018 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our data indicated that XIST was significantly upregulated in esophageal squamous cancerous tissues and cancer cell lines, as compared with that in the corresponding non-cancerous tissues and immortalized normal squamous epithelial cells.
|
29100288 |
2017 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
According to recent studies, long non-coding RNA X-inactive specific transcript (XIST) is involved in the development and progression of many malignant tumors including pancreatic cancer.
|
28295543 |
2017 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Previous studies have reported that lncRNA XIST regulates tumor malignancies in several cancers.
|
29212233 |
2017 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Functionally, XIST knockdown inhibited cancer cell proliferation and invasion, and induced apoptosis in vitro, and suppressed subcutaneous tumor growth in vivo.
|
28448993 |
2017 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Long non-coding RNAs (lncRNAs) XIST and HIF1A-AS1 have been shown to play important regulatory roles in cancer biology, and lncRNA-XIST and HIF1A-AS1 are upregulated in several cancers such as glioblastoma, breast cancer and thoracoabdominal aorta aneurysm, however, its value in the diagnosis of non-small cell lung cancer (NSCLC) is unclear.
|
26339353 |
2015 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The specific pathways whereby changes in X chromosome status and XIST expression occur in cancer remain incompletely described.
|
21212949 |
2011 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This indicates that the detection of XIST cloud in cancer cell is not synonymous of the presence of an inactive X chromosome.
|
19440381 |
2009 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
BRCA1 does not paint the inactive X to localize XIST RNA but may contribute to broad changes in cancer that impact XIST and Xi heterochromatin.
|
17146760 |
2007 |